Regeneron Protein-Drug Conjugates Camptothecin Analogs Patent
Summary
The USPTO granted Regeneron Pharmaceuticals, Inc. Patent US12605459B2 covering protein-drug conjugates that combine camptothecin analogs with glutaminyl-modified antibodies for targeted therapeutic delivery. The patent describes methods for producing antibody-drug conjugates using transglutaminase and 1,3-cycloaddition techniques. The granted patent provides Regeneron exclusive rights to the disclosed compositions and methods, with two claims covering the conjugate structures and their therapeutic applications.
What changed
The USPTO issued Patent US12605459B2 to Regeneron Pharmaceuticals, Inc. on April 21, 2026, covering protein-drug conjugates (antibody-drug conjugates) that incorporate camptothecin analogs as therapeutic payloads attached to glutaminyl-modified antibodies. The patent claims methods of producing these conjugates using transglutaminase and 1,3-cycloaddition (click chemistry) techniques.
For competitors in the antibody-drug conjugate and oncology therapeutics space, this patent represents an existing intellectual property barrier in the camptothecin-ADC field. Companies developing similar ADC technologies using glutamine modification and click chemistry linkage with topoisomerase I inhibitors should evaluate freedom-to-operate implications. Regeneron's patent specifically covers compositions and methods that may affect product development strategies in targeted cancer therapy.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
Grant US12605459B2 Kind: B2 Apr 21, 2026
Assignee
REGENERON PHARMACEUTICALS, INC.
Inventors
Amy Han
Abstract
Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic moieties, e.g., camptothecin analogs and/or derivatives. In certain embodiments, provided are specific and efficient methods for producing protein-drug constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and 1,3-cycloaddition techniques. Camptothecin analogs, antibody-drug conjugates, and compositions which comprise glutaminyl-modified antibodies and camptothecin analog payloads and are provided.
CPC Classifications
A61K 47/6889 A61K 47/55 A61K 47/64 A61K 47/67 A61K 47/68033 A61K 47/68037 A61K 47/6859 A61K 47/6869 A61K 31/4745 A61K 47/6879 A61P 35/00
Filing Date
2021-07-12
Application No.
17373524
Claims
2
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.